Online citations, reference lists, and bibliographies.
← Back to Search

Pursuit Of A Perfect Insulin

Alexander N Zaykov, J. Mayer, R. DiMarchi
Published 2016 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Insulin remains indispensable in the treatment of diabetes, but its use is hampered by its narrow therapeutic index. Although advances in peptide chemistry and recombinant DNA-based macromolecule synthesis have enabled the synthesis of structurally optimized insulin analogues, the growing epidemics of obesity and diabetes have emphasized the need for diabetes therapies that are more efficacious, safe and convenient. Accordingly, a broad set of drug candidates, targeting hyperglycaemia plus other disease abnormalities, is now progressing through the clinic. The development of an insulin therapy that is responsive to glucose concentration remains an ultimate goal, with initial prototypes now reaching the proof-of-concept stage. Simultaneously, the first alternatives to injectable delivery have progressed to registration.
This paper references
10.1360/01yc0295
Protein engineering of insulin: Two novel fast-acting insulins [B16Ala]insulin and [B26Ala]insulin
Z. Zhang (2008)
10.2337/diab.33.5.486
C-Peptide as a Measure of the Secretion and Hepatic Extraction of Insulin: Pitfalls and Limitations
K. Polonsky (1984)
10.1002/BIP.20734
Insulin structure and function.
J. Mayer (2007)
supporting acts and new players
Siddle (2011)
Controlling insulin bioavailability by crystal contact engineering
R Hilgenfeld (1992)
10.1007/s00253-004-1809-x
Therapeutic insulins and their large-scale manufacture
G. Walsh (2004)
10.1097/jnn.0b013e318274cc4d
A Review of the
Robert Wolpert (1985)
10.1016/S0084-3741(08)70010-6
A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes
L. Kennedy (2007)
10.1074/jbc.M800313200
Design of an Active Ultrastable Single-chain Insulin Analog
Q. Hua (2008)
10.1016/S0301-5629(02)00706-8
Ultrasound-mediated transdermal transport of insulin in vitro through human skin using novel transducer designs.
N. Smith (2003)
Merck to Acquire SmartCells, Inc. Merck Press Releases [online], http://www.merck.com/ licensing/our-partnership/SmartCells-partnership.html
Merck (2010)
10.1093/JHMAS/48.3.253
Rewriting medical history: Charles Best and the Banting and Best myth.
M. Bliss (1993)
Halogen-stabilized insulin
M·维斯 (2009)
10.1021/IE50183A004
THE PREPARATION OF INSULIN
C. Best (1925)
10.1016/0014-5793(76)80016-6
Oral administration of insulin by encapsulation within liposomes
H. M. Patel (1976)
10.1016/j.cell.2014.09.040
Generation of Functional Human Pancreatic β Cells In Vitro
F. Pagliuca (2014)
10.1038/333679A0
Monomeric insulins obtained by protein engineering and their medical implications
J. Brange (1988)
10.1038/492188a
Synthesis: A constructive debate
J. Keasling (2012)
10.1002/jcph.276
Single‐dose pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 in healthy subjects
V. Sinha (2014)
Total synthesis of crystalline bovine insulin.
Y. Kung (1965)
10.1016/j.cmet.2013.03.019
An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice.
W. Holland (2013)
10.1007/BF00417697
Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28),Pro(B29)] in IDDM
E. Torlone (2004)
10.1172/JCI27073
Insulin's direct effects on the liver dominate the control of hepatic glucose production.
D. Edgerton (2006)
Dance 501 inhaled human insulin has a dose-linear response and similar within-subject variability as rapid-acting insulin lispro
E Zijlstra (2015)
10.1021/IE50367A010
Preparation of Crystalline Insulin
R. G. Romans (1940)
10.1001/JAMA.1952.03680170021006
Zinc insulin preparations for single daily injection; clinical studies of new preparations with prolonged action.
K. Hallas-Møller (1952)
10.1073/PNAS.76.1.106
Expression in Escherichia coli of chemically synthesized genes for human insulin.
D. Goeddel (1979)
A systematic review of the literature
V. Montori (2002)
10.2147/DMSO.S21979
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
F. Wang (2012)
10.1111/dom.12087
Variability of glucose‐lowering effect as a limiting factor in optimizing basal insulin therapy: a review
J. Vora (2013)
10.1073/PNAS.83.18.6766
Secretion and processing of insulin precursors in yeast.
L. Thim (1986)
10.1002/mabi.201300120
Responsive materials for self-regulated insulin delivery.
Weitai Wu (2013)
10.1152/ajpendo.00348.2009
Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
J. Xu (2009)
10.2337/DC13-ER12B
Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care 2013;36(Suppl. 2):S226–S232
J. Vora (2013)
10.1111/j.1463-1326.2012.01658.x
Short‐term intensified insulin treatment in type 2 diabetes: long‐term effects on β‐cell function
R. Retnakaran (2012)
Liver enzyme results from 7 basal insulin peglispro (BIL) clinical trials in T1D and T2D
Hartman (2015)
Oral insulin reloaded a structured approach
E. Zijlstra (2014)
10.1002/dmrr.2469
Basal insulin analogues in the management of diabetes mellitus: what progress have we made?
D. Owens (2014)
10.1210/JCEM-56-6-1294
Hepatic removal of insulin in normal man: dose response to endogenous insulin secretion.
R. Eaton (1983)
10.2165/11536700-000000000-00000
Technosphere® Insulin
J. Neumiller (2012)
10.2337/dc12-2621
Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose Monitoring With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine
R. Bergenstal (2014)
10.1073/pnas.1424684112
Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates
D. Chou (2015)
10.2337/dc11-2503
Insulin Degludec/Insulin Aspart Administered Once Daily at Any Meal, With Insulin Aspart at Other Meals Versus a Standard Basal-Bolus Regimen in Patients With Type 1 Diabetes
I. Hirsch (2012)
10.2165/00003088-200847010-00002
Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glulisine
R. Becker (2008)
10.5040/9781474247115.0051
The pilot study.
C. Baird (2000)
10.1038/nbt0914-851a
Sanofi to propel inhalable insulin Afrezza into market
Jim Kling (2014)
10.1097/SA.0B013E31827F316E
Bariatric Surgery Versus Intensive Medical Therapy in Obese Patients With Diabetes
P. Schauer (2013)
10.1038/nm727
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
K. Miyawaki (2002)
IMAGINE 5
Buse (2015)
10.2337/db11-1578
A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control
V. Bhaskar (2012)
Hypoglycemia in Diabetes: Pathophysiology, Prevalence, and Prevention (American
P. Cryer (2012)
IMAGINE 4
Blevins (2015)
Crystalline insulinconjugates
T. C. Zion (2010)
10.1007/s40266-013-0128-2
Elderly Patients with Diabetes Experience a Lower Rate of Nocturnal Hypoglycaemia with Insulin Degludec than with Insulin Glargine: A Meta-Analysis of Phase IIIa Trials
Christopher H. Sorli (2013)
10.1016/J.ADDR.2007.08.019
Current challenges in non-invasive insulin delivery systems: a comparative review.
E. Khafagy (2007)
10.1007/s001250051414
Translating the Diabetes Control and Complications Trial (DCCT) into clinical practice: overcoming the barriers
B. Zinman (1997)
10.1097/00019616-199503000-00013
Joslinʼs Diabetes Mellitus
C. Kahn (1995)
10.1371/journal.pone.0059524
Glucose-Reducing Effect of the ORMD-0801 Oral Insulin Preparation in Patients with Uncontrolled Type 1 Diabetes: A Pilot Study
R. Eldor (2013)
10.1038/nrendo.2014.142
Diabetes: Insulin pump therapy for type 2 diabetes mellitus
J. Pickup (2014)
10.1007/s10047-004-0251-2
Comparison between closed-loop portal and peripheral venous insulin delivery systems for an artificial endocrine pancreas
T. Sekigami (2004)
10.1021/ja311408y
Fully convergent chemical synthesis of ester insulin: determination of the high resolution X-ray structure by racemic protein crystallography.
Michal Avital-Shmilovici (2013)
10.2337/db13-0334
Identification of a Small Molecular Insulin Receptor Agonist With Potent Antidiabetes Activity
Guifen Qiang (2014)
Safety and efficacy of ultra-rapid-acting human insulin formulation BIOD-123 in patients with type 1 diabetes
A Krasner (2014)
OI338GT (NN1953) Phase II trial
Novo Nordisk (2016)
10.1111/dom.12068
Newer insulin analogs: advances in basal insulin replacement
B. Zinman (2013)
10.1111/dom.12223
Contrasting weight changes with LY2605541, a novel long‐acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM
S. Jacober (2014)
10.1136/bmj.299.6696.415
NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue.
S. Jørgensen (1989)
10.2337/dc14-0001
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
J. Rosenstock (2014)
10.1056/NEJMc1206221
Insulin-pump therapy for type 1 diabetes mellitus.
I. Blumer (2012)
One-year efficacy and safety of IDegLira in patients with type 2 diabetes
S. Gough (2014)
10.1073/pnas.0830026100
Assembly of high-affinity insulin receptor agonists and antagonists from peptide building blocks
L. Schäffer (2003)
10.1021/ol400149j
Concise synthetic routes to human insulin.
F. Liu (2013)
10.1210/MEND-3-8-1263
Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man.
D. Moller (1989)
10.1152/AJPENDO.00041.2004
Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes.
C. Meyer (2004)
Lilly Ends Basal Insulin Peglispro Development Program. Lilly Investor Press Release [online], https://investor.lilly.com/releasedetail
Eli Lilly (2014)
what progress have we made? Diabetes Metab
D. R. Owens (2014)
10.1177/193229681200600210
Insulin Fibrillation and Protein Design: Topological Resistance of Single-Chain Analogs to Thermal Degradation with Application to a Pump Reservoir
Nelson F B Phillips (2012)
10.1073/PNAS.78.3.1391
Human insulin prepared by recombinant DNA techniques and native human insulin interact identically with insulin receptors.
L. Keefer (1981)
10.1046/j.1464-5491.2003.01076.x
Alternative routes of insulin delivery
D. Owens (2003)
10.1210/JC.2003-030738
The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
T. Vilsbøll (2003)
10.1177/0193945910394380
Systematic Review
F. Nabavi (2012)
The Prolongation of Insulin Action
C. Best (1937)
10.1177/193229681300700228
Oral Insulin Delivery: How Far are We?
P. Fonte (2013)
10.1038/nrendo.2011.32
Closed-loop insulin delivery: from bench to clinical practice
R. Hovorka (2011)
10.1002/j.1460-2075.1990.tb07416.x
Functionally distinct insulin receptors generated by tissue‐specific alternative splicing.
L. Mosthaf (1990)
10.1371/journal.pone.0051972
Agonism and Antagonism at the Insulin Receptor
L. Knudsen (2012)
VICTOZA ADD-ON)
Mathieu (2014)
a multicentre randomised trial
Rosenstock (2010)
10.1371/journal.pone.0020288
Engineering of Insulin Receptor Isoform-Selective Insulin Analogues
Tine Glendorf (2011)
10.1002/anie.201001151
Design and folding of [GluA4(ObetaThrB30)]insulin ("ester insulin"): a minimal proinsulin surrogate that can be chemically converted into human insulin.
Y. Sohma (2010)
10.1016/j.jvs.2005.02.005
Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery.
L. Sjöström (2004)
Insulin analogues with chlorinated amino acids
마이클 웨이스 (2010)
10.1111/dom.12196
PEGylated insulin Lispro, (LY2605541)—a new basal insulin analogue
T. M. Caparrotta (2014)
10.2337/diab.15.3.219
Combined Use of Regular and Crystalline Protamine (NPH) Insulins in the Treatment of Severe Diabetes
W. Oakley (1966)
10.1007/s00125-009-1487-4
Differential effects of insulin detemir and neutral protamine Hagedorn (NPH) insulin on hepatic glucose production and peripheral glucose uptake during hypoglycaemia in type 1 diabetes
F. Smeeton (2009)
leveraging hydrodynamic size to develop a novel basal insulin
Hansen (2012)
10.1055/S-2005-870584
Efficacy and safety of insulin glulisine in patients with type 1 diabetes.
M. Dreyer (2005)
advances in basal insulin replacement
Zinman (2013)
10.1242/dmm.009621
Anti-obesity drugs: past, present and future
R. Rodgers (2012)
10.1042/bj0490481
The amino-acid sequence in the phenylalanyl chain of insulin. 2. The investigation of peptides from enzymic hydrolysates.
F. Sanger (1951)
10.1042/BJ0490463
The amino-acid sequence in the phenylalanyl chain of insulin. I. The identification of lower peptides from partial hydrolysates.
F. Sanger (1951)
10.1016/S1097-2765(01)00203-9
Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic beta cells.
B. Leibiger (2001)
Insulin Pump Therapy for Type 2 Diabetes Mellitus Accompanied with Community-acquired Pneumonia
Yang Xiao-hon (2010)
10.1097/SLA.0b013e3182a5034b
Can Diabetes Be Surgically Cured? Long-Term Metabolic Effects of Bariatric Surgery in Obese Patients with Type 2 Diabetes Mellitus
S. Brethauer (2013)
10.1530/JME-11-0022
Signalling by insulin and IGF receptors: supporting acts and new players.
K. Siddle (2011)
10.1080/09674845.2012.12002443
A history of blood glucose meters and their role in self-monitoring of diabetes mellitus
S. Clarke (2012)
10.1016/j.jneuroim.2012.01.006
From bench to MS bedside: Challenges translating biomarker discovery to clinical practice
S. Rajasekharan (2012)
10.1111/dom.12097
Superior glycaemic control with once‐daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial
Y. Onishi (2013)
10.1007/s001250050797
The effect of portal and peripheral insulin delivery on carbohydrate and lipid metabolism in a miniature pig model of human IDDM
J. Canavan (1997)
10.1021/JA051038K
Reversible insulin self-assembly under carbohydrate control.
T. Hoeg-Jensen (2005)
10.2337/dc10-2105
Short-Term Intensive Therapy in Newly Diagnosed Type 2 Diabetes Partially Restores Both Insulin Sensitivity and β-Cell Function in Subjects With Long-Term Remission
Y. Hu (2011)
10.1111/j.1463-1326.2012.01628.x
Combining GLP‐1 receptor agonists with insulin: therapeutic rationales and clinical findings
J. Holst (2013)
10.1111/j.1463-1326.2009.01150.x
Oral insulin – a review of current status
H. Iyer (2010)
10.1212/01.wnl.0000184442.02551.4b
A randomized crossover study of bee sting therapy for multiple sclerosis
T. Wesselius (2005)
10.1021/JA00973A068
The synthesis of bovine insulin by the solid phase method.
A. Marglin (1966)
10.2337/diab.5.1.7
The Lente Insulins
K. Hallas-Mø (1956)
10.1016/S0149-2918(97)80073-2
Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group.
J. Anderson (1997)
10.1023/B:PHAM.0000036926.54824.37
The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin
S. Havelund (2004)
10.1089/dia.2009.0127
The role of basal insulin and glucagon-like peptide-1 agonists in the therapeutic management of type 2 diabetes--a comprehensive review.
S. Garg (2010)
Glucose dependent release of insulin from glucose sensing insulin derivatives
T Hoeg-Jensen (2008)
10.1016/j.bcp.2009.05.037
Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.
B. Kerr (2009)
10.1053/J.GASTRO.2007.03.054
Biology of incretins: GLP-1 and GIP.
L. Baggio (2007)
Insulin therapy for management of type 2 diabetes mellitus: strategies for initiation and long-term patient adherence.
Steven H. Barag (2011)
10.1016/j.biomaterials.2013.05.066
Perfusion-decellularized pancreas as a natural 3D scaffold for pancreatic tissue and whole organ engineering.
Saik-Kia Goh (2013)
10.1002/anie.201310735
A synthetic route to human insulin using isoacyl peptides.
F. Liu (2014)
10.2337/DIACARE.23.8.1124
Novel hepatoselective insulin analog: studies with a covalently linked thyroxyl-insulin complex in humans.
F. Shojaee-Moradie (2000)
randomized, parallel, treat to target trial comparing insulin detemir with NPH insulin as add on therapy to oral glucoselowering drugs in insulin-naive people with type 2 diabetes
K Hermansen (2006)
10.1111/dom.12052
Insulin degludec: overview of a novel ultra long‐acting basal insulin
S. Gough (2013)
The lente insulins.
K. Hallas-Møller (1956)
10.2337/dc12-0067
Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes
J. Rosenstock (2013)
10.2337/dc13-2743
Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges?
P. Home (2014)
10.1002/psc.1264
Backbone cyclic insulin
A. Andersen (2010)
Insulin degludec in a flexible daily dosing regimen provides similar glycaemic control without increasing rates of hypoglycaemia compared to dosing the same time daily in type 2 diabetes
K. Birkeland (2011)
GLP 1 and GIP
L. L. Baggio (2007)
10.1021/JA01059A043
Insulin Peptides. X. The Synthesis of the B-Chain of Insulin and Its Combination with Natural or Synthetis A-Chin to Generate Insulin Activity
P. Katsoyannis (1964)
10.1042/BJ20110880
Receptor-isoform-selective insulin analogues give tissue-preferential effects.
S. Vienberg (2011)
Single-chain insulin agonists exhibiting high activity at the insulin receptor
DiMarchi (2011)
10.1002/cbic.200800430
Total Synthesis of desB30 Insulin Analogues by Biomimetic Folding of Single‐Chain Precursors
A. P. Tofteng (2008)
10.1056/NEJM199309303291401
The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long‐Term Complications in Insulin‐Dependent Diabetes Mellitus
D. Nathan (1993)
10.1124/jpet.114.221309
Differential Pathway Coupling of the Activated Insulin Receptor Drives Signaling Selectivity by XMetA, an Allosteric Partial Agonist Antibody
Daniel H Bedinger (2015)
10.1353/man.2003.0087
A Breath of Fresh Air (review)
L. Lent (2003)
10.1177/193229681000400304
Practical Aspects of Insulin Pen Devices
T. Pearson (2010)
10.1007/BF00262008
Mechanism of action of insulin and insulin analogues
C. Tompkins (2004)
10.1089/DIA.2014.1506
Insulin Pens and New Ways of Insulin Delivery
HeinemannLutz (2014)
10.1016/S2213-8587(14)70174-3
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
S. Gough (2014)
10.1111/dom.12262
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD‐ON)
C. Mathieu (2014)
10.1042/BJ0530366
The amino-acid sequence in the glycyl chain of insulin. II. The investigation of peptides from enzymic hydrolysates.
F. Sanger (1953)
10.1126/scitranslmed.3007218
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
B. Finan (2013)
10.1210/er.2008-0047
Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.
A. Belfiore (2009)
10.1530/JOE-10-0419
Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice.
V. Gault (2011)
Preprandial oral insulin (ORMD-0801) reduces rapid-acting insulin requirements and fasting glucose levels in T1DM patients (poster)
M. Kidron (2015)
strategies for initiation and longterm patient adherence
Barag (2011)
Chemically and thermodynamically stable insulin analogues and improved methods for their production
M. H. Stowell (2015)
10.2337/db13-0973
Proinsulin-Transferrin Fusion Protein as a Novel Long-Acting Insulin Analog for the Inhibition of Hepatic Glucose Production
Y. Wang (2014)
10.1038/nrendo.2013.145
The use of stem cells for pancreatic regeneration in diabetes mellitus
L. Bouwens (2013)
10.1111/j.1365-2710.2009.01048.x
Insulin pumps: from inception to the present and toward the future
F. Alsaleh (2010)
10.2337/dc14-0210
Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects
R. Henry (2014)
synthesis, structure, and therapeutic implications
Hua (2008)
Novo Nordisk Receives FDA Approval for Tresiba® (insulin degludec injection) for Adults with Type 1 and Type 2 Diabetes
Novo Nordisk (2015)
10.1201/9781420086836.ch15
Past, present--and future?
D. Holdstock (2005)
10.1021/cb400792s
Chemical synthesis of insulin analogs through a novel precursor.
Alexander N Zaykov (2014)
Novel very long-acting insulin analog (HM12470) with potential for onceweekly dosing has a favorable PK, PD and mitogenic profile. American Diabetes Association’s 74th Scientific Sessions [online
Hwang (2014)
10.1016/S0140-6736(10)60632-0
Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial
J. Rosenstock (2010)
10.1093/nar/gkv767
Agonistic aptamer to the insulin receptor leads to biased signaling and functional selectivity through allosteric modulation
Na-Oh Yunn (2015)
Synergistic action of PE0139, a super-long-acting basal insulin & PB1023 a weekly GLP1 receptor agonist
S. Arnold (2015)
10.1108/jd.2011.27867bae.001
Comparative review
K. H. Wolf (2011)
results of a Phase 3, open-label, randomised, 26 week, treat to target trial in insulin-naive patients with type 2 diabetes
Gough (2014)
10.2337/DIACLIN.19.2.66
Is There a Need for a Better Basal Insulin
R. Guthrie (2001)
Therapeutic agents comprising insulin amino acid sequences
조엣 제임스 (2012)
10.2337/DIACARE.24.4.631
Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
J. Rosenstock (2001)
10.2337/diab.43.3.396
[Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin
D. C. Howey (1994)
10.2337/diab.35.3.311
In Vivo Deactivation of Proinsulin Action on Glucose Disposal and Hepatic Glucose Production in Normal Man
H. Glauber (1986)
how far are we? J
P. Fonte (2013)
W99-S32 a soluble, basal insulin analog
S Myers (1995)
10.1111/dom.12498
One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial
S. Gough (2015)
10.1186/s12934-014-0141-0
Cell factories for insulin production
N. Baeshen (2014)
10.1126/SCIENCE.6337396
Human insulin from recombinant DNA technology.
I. Johnson (1983)
10.1038/nbt0413-266
FDA dashes Novo's hopes
E. Dorey (2013)
10.1126/science.177.4049.623
Human Insulin: Facile Synthesis by Modification of Porcine Insulin
M. A. Ruttenberg (1972)
10.1021/jm100527s
Peptide and Protein Design for Biopharmaceutical Applications
W. Kazmierski (2010)
10.1111/dom.12025
Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
R. Balena (2013)
10.1001/jama.2014.6316
Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010.
K. Lipska (2014)
10.1089/dia.2014.0193
Closed-loop system in the management of diabetes: past, present, and future.
V. Shah (2014)
10.1021/cb4002624
Discovery of high potency, single-chain insulin analogs with a shortened B-chain and nonpeptide linker.
Zachary P Kaur (2013)
IMAGINE 3
Bergenstal (2015)
10.2337/dc13-2908
Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial
G. Fulcher (2014)
10.1007/s00592-013-0481-y
A 7-year follow-up retrospective, international, multicenter study of insulin pump therapy in children and adolescents with type 1 diabetes
C. Mameli (2013)
Use of PKPD model to design and analyze results of a euglycemic clamp study for a very long-acting insulin analogue HM12470
Y Huh (2015)
10.1074/jbc.M704599200
Activation of the Insulin Receptor by Insulin and a Synthetic Peptide Leads to Divergent Metabolic and Mitogenic Signaling and Responses*
M. Jensen (2007)
10.1089/dia.2009.0112
Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes.
Erin C Cobry (2010)
10.1111/j.2040-1124.2012.00203.x
The role of leptin in glucose homeostasis
H. Denroche (2012)
10.2337/DIACARE.21.11.1904
Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.
P. Home (1998)
10.2337/diab.20.8.552
Insulin Across Respiratory Mucosae by Aerosol Delivery
F. W. Wigley (1971)
10.1038/NBT1207-1331
Pfizer dumps Exubera
G. Mack (2007)
10.1111/dom.12117
Hepatoselectivity and the evolution of insulin
R. Herring (2014)
10.1046/j.1464-5491.2000.00380.x
Insulin aspart vs. human insulin in the management of long‐term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial
P. Home (2000)
10.1038/ijo.2013.80
The melanocortin-4 receptor as target for obesity treatment: a systematic review of emerging pharmacological therapeutic options
L. Fani (2014)
10.2337/db14-0266
Changes in Glucose and Fat Metabolism in Response to the Administration of a Hepato-Preferential Insulin Analog
D. Edgerton (2014)
10.1016/0006-291X(89)92439-X
Alternative splicing of human insulin receptor messenger RNA.
S. Seino (1989)
10.1039/c3cs60436e
Emerging micro- and nanotechnology based synthetic approaches for insulin delivery.
Ran Mo (2014)
Total synthesis of crystalline bovine insulin.
Kung Yt (1965)
10.1021/cr200027j
Organization of glucose-responsive systems and their properties.
Q. Wu (2011)
10.2337/DIABETES.54.6.1649
Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans.
J. Meier (2005)
10.2337/DIABETES.54.1.251
Development of a long-acting insulin analog using albumin fusion technology.
A. Duttaroy (2005)
10.1007/s11095-012-0739-z
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
I. Jonassen (2012)
linear dose-response and faster absorption than insulin Lispro (LIS)
Andersen (2015)
10.1371/journal.pone.0040156
GIP-Overexpressing Mice Demonstrate Reduced Diet-Induced Obesity and Steatosis, and Improved Glucose Homeostasis
S. Kim (2012)
10.1055/S-2005-865806
Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
R. Becker (2005)
Financial report for the period 1 January 2014
Novo Nordisk (2014)
10.1016/s0021-9258(18)85220-6
ON THE PREPARATION OF INSULIN
M. Somogyi (1924)



This paper is referenced by
10.1021/acs.accounts.7b00288
Novel Methods for the Chemical Synthesis of Insulin Superfamily Peptides and of Analogues Containing Disulfide Isosteres.
M. Hossain (2017)
10.1134/S0006297918140122
Analysis of Insulin Analogs and the Strategy of Their Further Development
O. Selivanova (2018)
10.1007/s11426-019-9699-3
Responsive boron biomaterials and their biomedical applications
W. Chen (2020)
10.1039/c9ra08284k
Calculating the absolute binding free energy of the insulin dimer in an explicit solvent
Qiankun Gong (2020)
10.1038/s41598-018-37568-6
Enhanced anti-tumor activity of the Multi-Leu peptide PACE4 inhibitor transformed into an albumin-bound tumor-targeting prodrug
A. Kwiatkowska (2019)
10.1016/j.peptides.2019.04.004
BZ043, a novel long-acting amylin analog, reduces gastric emptying, food intake, glycemia and insulin requirement in streptozotocin-induced diabetic rats
C. V. M. F. Nascimento (2019)
10.1016/j.addr.2018.11.008
Therapeutic medications against diabetes: What we have and what we expect.
C. Hu (2018)
10.1021/acs.biomac.8b00215
pH- and Amylase-Responsive Carboxymethyl Starch/Poly(2-isobutyl-acrylic acid) Hybrid Microgels as Effective Enteric Carriers for Oral Insulin Delivery.
L. Liu (2018)
10.1080/17425247.2020.1738381
Comparison of glucose variability in patients with type 2 diabetes administrated glargine with needle-free jet injector and conventional insulin pen
Ying Sun (2020)
10.1021/acs.accounts.7b00227
Synthetic Advances in Insulin-like Peptides Enable Novel Bioactivity.
F. Liu (2017)
10.7554/eLife.46170
Trans-toxin ion-sensitivity of charybdotoxin-blocked potassium-channels reveals unbinding transitional states
Hans Moldenhauer (2019)
10.1002/psc.3017
Characterization of an insulinotropic peptide from skin secretions of Odorrana andersonii
Wei-Jie Shang (2017)
10.4155/fmc-2020-0013
Recent advances in the chemical synthesis of insulin and related peptides.
F. Brunel (2020)
10.1097/MED.0000000000000345
Development of glucose-responsive ‘smart’ insulin systems
N. Rege (2017)
10.1021/acs.biochem.8b01094
Display of Single-Chain Insulin-like Peptides on a Yeast Surface.
Mi-Young Jeong (2019)
10.1016/j.addr.2018.01.016
Improving long‐term subcutaneous drug delivery by regulating material‐bioenvironment interaction☆
W. Chen (2018)
10.1172/jci.insight.97476
A glucose-responsive insulin therapy protects animals against hypoglycemia.
R. Yang (2018)
10.1038/nrendo.2017.39
Insulin analogues in type 1 diabetes mellitus: getting better all the time
C. Mathieu (2017)
10.1016/J.COISB.2017.06.005
Closed-loop control systems – The quest for precision therapies for diabetes
Mingqi Xie (2017)
10.1016/j.molmet.2020.101121
Characterization of viral insulins reveals white adipose tissue-specific effects in mice
Martina Chrudinová (2020)
10.1021/jacs.9b05365
O-GlcNAc engineering of GPCR peptide-agonists improves their stability and in vivo activity.
Paul M. Levine (2019)
10.1002/ddr.21408
Small Scaffolds, Big Potential: Developing Miniature Proteins as Therapeutic Agents
Justin M Holub (2017)
10.1039/c9md00252a
Molecular evolution of peptides by yeast surface display technology.
Sara Linciano (2019)
10.1002/adtp.201900128
Long‐Lasting Designer Insulin with Glucose‐Dependent Solubility Markedly Reduces Risk of Hypoglycemia
Yibo Qiu (2019)
10.1016/j.addr.2018.12.001
Strategies for improving diabetic therapy via alternative administration routes that involve stimuli-responsive insulin-delivering systems.
Yu-Jung Lin (2018)
10.1002/cpt.1215
Clinical Evaluation of MK‐2640: An Insulin Analog With Glucose‐Responsive Properties
A. Krug (2019)
10.1021/acs.jmedchem.7b01331
Insulin-like Growth Factor 1 Analogs Clicked in the C Domain: Chemical Synthesis and Biological Activities.
K. Macháčková (2017)
10.3929/ETHZ-B-000165412
Human Designer Cells: From Remote-Controlled Gene Regulation to Self-sufficient Therapeutic Biocomputers
Mingqi Xie (2017)
10.1016/j.peptides.2017.11.012
Glucose-lowering therapies in type 2 diabetes: Opportunities and challenges for peptides
C. Bailey (2018)
10.1002/POLA.29225
Replacement of ProB28 by pipecolic acid protects insulin against fibrillation and slows hexamer dissociation
K. Y. Fang (2019)
10.1016/j.actbio.2019.05.051
Engineering the vasculature for islet transplantation.
D. Bowers (2019)
10.1126/science.aaf4006
β-cell–mimetic designer cells provide closed-loop glycemic control
Mingqi Xie (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar